Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2141815

SciClone Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Description:

SciClone Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “SciClone Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the SciClone Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, SciClone Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from SciClone Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- SciClone Pharmaceuticals, Inc. - Brief SciClone Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of SciClone Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of SciClone Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the SciClone Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate SciClone Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of SciClone Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the SciClone Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with SciClone Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of SciClone Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of SciClone Pharmaceuticals, Inc.; SciClone Pharmaceuticals, Inc. - Key Therapeutics; SciClone Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; SciClone Pharmaceuticals, Inc. - News; SciClone Pharmaceuticals, Inc. - Latest Updates; SciClone Pharmaceuticals, Inc. - Pipeline; SciClone Pharmaceuticals, Inc. - Discontinued/Dormant Projects

Contents:

List of Tables
List of Figures
SciClone Pharmaceuticals, Inc. Snapshot
SciClone Pharmaceuticals, Inc. Overview
Key Information
Key Facts
SciClone Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
SciClone Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
SciClone Pharmaceuticals, Inc. – Pipeline Products Glance
SciClone Pharmaceuticals, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
SciClone Pharmaceuticals, Inc. – Drug Profiles
Budesonide
Product Description
Mechanism of Action
R&D Progress
Erwinase
Product Description
Mechanism of Action
R&D Progress
Formoterol
Product Description
Mechanism of Action
R&D Progress
Thioctacid-Intravenous
Product Description
Mechanism of Action
R&D Progress
Thioctacid-Oral
Product Description
Mechanism of Action
R&D Progress
Tramadol
Product Description
Mechanism of Action
R&D Progress
SciClone Pharmaceuticals, Inc. – Pipeline Analysis
SciClone Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
SciClone Pharmaceuticals, Inc. – Pipeline Products By Target
SciClone Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
SciClone Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
SciClone Pharmaceuticals, Inc. – Recent Pipeline Updates
SciClone Pharmaceuticals, Inc. - Dormant Projects
SciClone Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
RP101 + Gemcitabine
RP101
SCV-07
SCV-07 + Ribavirin
SciClone Pharmaceuticals, Inc. – Company Statement
SciClone Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SciClone Pharmaceuticals, Inc., Recent Developments
SciClone Pharmaceuticals, Inc.- Press Release
Mar 02, 2012: SciClone Announces Results Of Interim Analysis Of Phase II SCV-07 Oral Mucositis Trial
Nov 30, 2009: SciClone Announces Commencement And Complete Enrollment Of Clinical Study Examining Zadaxin’s Ability To Enhance The H1N1 Vaccine
Nov 23, 2009: SciClone Announces Enrollment Completion In Phase 2 Oral Mucositis Trial Of SCV-07
Nov 12, 2009: SciClone Pharmaceuticals Announces Presentations Of SCV-07 Data Annual AACR-NCI-EORTC Meeting As Well As Cold Spring Harbor Laboratory's Winter Biotech Conference Meetings
Oct 21, 2009: SciClone Announces Enrollment Of First Patient In Its Phase 2 Trial Of SCV-07 In Hepatitis C
Financial Deals Landscape
SciClone Pharmaceuticals, Inc., Deals Summary
SciClone Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
NovaMed Acquires 51% Interest In Interventional Pain Management Center
NovaMed Acquires 62.5% Stake In Surgery Center Of Kalamazoo
NovaMed Acquires 54% St. Peters Ambulatory Surgery Center
NovaMed Acquires 51% Interest In Ophthalmic Ambulatory Surgery
NovaMed Acquires 65% Stake In Surgery Center Of Cleveland
NovaMed Acquires John Kenyon Center for Eye Surgery
NovaMed Acquires 61% Stake In Clearview Surgical Institute
NovaMed Acquires Eye Surgery Center of Arkansas
NovaMed Acquires Acquires 55% Stake In American Surgery Centers Of South Texas
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of Maryville
NovaMed Acquires 65% Stake In Preston Plaza Surgery Center
NovaMed Acquires 51% Stake In Fremont Ambulatory Surgicenter
NovaMed Acquires 51% Stake In Center For Outpatient Surgery
NovaMed Acquires 25% Stake In Eye Care And Surgery Center Of Fort Lauderdale
NovaMed Acquires 60% Stake In Palm Beach
NovaMed Acquires Majority Stake In Center For Reconstructive Surgery
NovaMed Acquires Majority Stake In Altamonte Surgery Center
NovaMed Acquires Two Eye Surgery Centers In New Hampshire
Venture Financing
NovaMed Pharma Secures $13.8 Million In Series B Financing
NovaMed Pharma Secures $5 Million In Series A Financing
Partnerships
Sanofi-Aventis Enters Into Co-Promotion Agreement With NovaMed Pharma
NovaMed Pharma Enters Into Distribution Agreement With Meda
Biocompatibles International Signs Agreement With SciClone Pharma
SciClone Pharma Enters Into Co-Development Agreement With Nektar Therapeutics
Licensing Agreements
Orexo Enters Into Licensing Agreement With NovaMed
SciClone Enteres Into Licensing Agreement With Resistys
SciClone Pharma Enters Into Licensing Agreement For SCV-07
SciClone Pharma Enters Into Licensing Agreement With APR Applied Pharma
NovaMed Pharma Enters Into Licensing Agreement With Iroko Pharma
NovaMed Pharma Enters Into Licensing Agreement With EUSA Pharma
BioAlliance Pharma Enters Into Exclusive Licensing Agreement With NovaMed Pharma
RESprotect Enters Into Licensing Agreement With SciClone Pharma
Avantogen Oncology Enters Into Licensing Agreement With SciClone Pharma
NovaMed Pharma Enters Into Licensing Agreement With Dr. Reddy's
SciClone Enteres Into Agreement With Biocomaptibles
Equity Offering
SciClone Pharma Files Registration Statement For Public Offering Of Securities For $100 Million
Debt Offering
NovaMed Completes Private Placement Of 1% Convertible Senior Subordinated Notes For $75 Million
Asset Transactions
Bronson Healthcare Acquires Minority Stake In Surgery Center of Kalamazoo
NovaMed Sells Majority Stake In Ambulatory Surgery Center Of Laredo
NovaMed Sells Majority Stake In Ambulatory Surgery Center Of Thibodaux
NovaMed Sells Ambulatory Surgery Center In Missouri
Midelfart Sonesson Acquires Product Rights From NovaMed
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of Columbus
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of Richmond
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of Chattanooga
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of New Albany
Acquisition
Surgery Center Holdings Completes Acquisition Of NovaMed
SciClone Pharma Acquires NovaMed Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
SciClone Pharmaceuticals, Inc., Key Information
SciClone Pharmaceuticals, Inc., Key Facts
SciClone Pharmaceuticals, Inc. – Pipeline by Indication, 2012
SciClone Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
SciClone Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
SciClone Pharmaceuticals, Inc. – Filed, 2012
SciClone Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
SciClone Pharmaceuticals, Inc. - Pipeline By Target, 2012
SciClone Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
SciClone Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
SciClone Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
SciClone Pharmaceuticals, Inc. - Dormant Developmental Projects,2012
SciClone Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2012
SciClone Pharmaceuticals, Inc., Subsidiaries
SciClone Pharmaceuticals, Inc., Deals Summary
NovaMed Acquires 51% Interest In Interventional Pain Management Center
NovaMed Acquires 62.5% Stake In Surgery Center Of Kalamazoo
NovaMed Acquires 54% St. Peters Ambulatory Surgery Center
NovaMed Acquires 51% Interest In Ophthalmic Ambulatory Surgery
NovaMed Acquires 65% Stake In Surgery Center Of Cleveland
NovaMed Acquires John Kenyon Center for Eye Surgery
NovaMed Acquires 61% Stake In Clearview Surgical Institute
NovaMed Acquires Eye Surgery Center of Arkansas
NovaMed Acquires Acquires 55% Stake In American Surgery Centers Of South Texas
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of Maryville
NovaMed Acquires 65% Stake In Preston Plaza Surgery Center
NovaMed Acquires 51% Stake In Fremont Ambulatory Surgicenter
NovaMed Acquires 51% Stake In Center For Outpatient Surgery
NovaMed Acquires 25% Stake In Eye Care And Surgery Center Of Fort Lauderdale
NovaMed Acquires 60% Stake In Palm Beach
NovaMed Acquires Majority Stake In Center For Reconstructive Surgery
NovaMed Acquires Majority Stake In Altamonte Surgery Center
NovaMed Acquires Two Eye Surgery Centers In New Hampshire
NovaMed Pharma Secures $13.8 Million In Series B Financing
NovaMed Pharma Secures $5 Million In Series A Financing
Sanofi-Aventis Enters Into Co-Promotion Agreement With NovaMed Pharma
NovaMed Pharma Enters Into Distribution Agreement With Meda
Biocompatibles International Signs Agreement With SciClone Pharma
SciClone Pharma Enters Into Co-Development Agreement With Nektar Therapeutics
Orexo Enters Into Licensing Agreement With NovaMed
SciClone Enteres Into Licensing Agreement With Resistys
SciClone Pharma Enters Into Licensing Agreement For SCV-07
SciClone Pharma Enters Into Licensing Agreement With APR Applied Pharma
NovaMed Pharma Enters Into Licensing Agreement With Iroko Pharma
NovaMed Pharma Enters Into Licensing Agreement With EUSA Pharma
BioAlliance Pharma Enters Into Exclusive Licensing Agreement With NovaMed Pharma
RESprotect Enters Into Licensing Agreement With SciClone Pharma
Avantogen Oncology Enters Into Licensing Agreement With SciClone Pharma
NovaMed Pharma Enters Into Licensing Agreement With Dr. Reddy's
SciClone Enteres Into Agreement With Biocomaptibles
SciClone Pharma Files Registration Statement For Public Offering Of Securities For $100 Million
NovaMed Completes Private Placement Of 1% Convertible Senior Subordinated Notes For $75 Million
Bronson Healthcare Acquires Minority Stake In Surgery Center of Kalamazoo
NovaMed Sells Majority Stake In Ambulatory Surgery Center Of Laredo
NovaMed Sells Majority Stake In Ambulatory Surgery Center Of Thibodaux
NovaMed Sells Ambulatory Surgery Center In Missouri
Midelfart Sonesson Acquires Product Rights From NovaMed
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of Columbus
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of Richmond
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of Chattanooga
NovaMed Sells Minority Stake In Ambulatory Surgery Center Of New Albany
Surgery Center Holdings Completes Acquisition Of NovaMed
SciClone Pharma Acquires NovaMed Pharma

List of Figures
SciClone Pharmaceuticals, Inc. – Pipeline by Indication, 2012
SciClone Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
SciClone Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
SciClone Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
SciClone Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
SciClone Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Wednesday, May 22, 2013
11:41:44 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

SciClone Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Web Address

http://www.researchandmarkets.com/reports/2141815

Office Code

OC8DIQSOSRTXQQ

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Wednesday, May 22, 2013
11:41:44 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

SciClone Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)